Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 1/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.53 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.53 |
| ▸ | MITF | O75030 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880064 | 1.00 | TACR2 (0.86) | TACR2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL5216320 | 0.94 | TACR2 (0.78) | TACR2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL13220784 | 0.93 | TACR2 (1.00) | TACR2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL14682675 | 0.93 | TACR2 (0.80) | TACR2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL413085 | 0.91 | TACR2 (0.78) | TACR2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL2556112 | 0.90 | TACR2 (0.76) | TACR2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL414613 | 0.89 | TACR2 (0.70) | TACR2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL18002005 | 0.87 | TACR2 (0.68) | TACR2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL5219137 | 0.87 | TACR2 (0.67) | TACR2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL28771925 | 0.86 | TACR2 (0.67) | TACR2ALDH1A1MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3828162-B1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES COMPRISING THE SAME | AUTOTAC INC (KR) | 2025-07-09 | — | — | EP | disclosed |
| US-11981618-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | AUTOTAC INC. (KR) | 2024-05-14 | — | — | US | disclosed |
| US-20210347749-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PROTEINOPATHIES COMPRING THE SAME | PROTECH CO., LTD. (KR) | 2021-11-11 | — | — | US | disclosed |
| EP-3828162-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, ALLEVIATING, OR TREATING PROTEIN ABNORMALITY DISORDERS | Protech Co., Ltd. (KR) | 2021-06-02 | — | — | EP | disclosed |
| US-6506755-B2 | 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis | HOFFMANN-LA ROCHE INC. | 2003-01-14 | — | — | US | disclosed |
| US-20020037901-A1 | Thiazolidinecarboxyl acids | HOFFMANN-LA ROCHE INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1189894-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001057006-A1 | THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-09 | — | — | WO | disclosed |
| US-4568490-A | REDUCTIVE CONDENSATION WITH A CARBONYL COMPOUND | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1986-02-04 | — | — | US | disclosed |
| US-4537880-A | Aminopropylaminobleomycin derivatives and process for preparation thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347749-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PROTEINOPATHIES COMPRING THE SAME | SQSTM1, ATG7, BECN1 | TACR2 4608/4885ALDH1A1 4732/4885MAPT 68/4885 |
| US-20020037901-A1 | Thiazolidinecarboxyl acids | TPMT, NAT1, THRA | TACR2 1488/4885ALDH1A1 27/4885MAPT 3924/4885 |
| US-11981618-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | SQSTM1, ATG7, BECN1 | TACR2 4532/4885ALDH1A1 4713/4885MAPT 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.